🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thanks for attending the CIBMTR Infection and Immune Reconstitution Working Committee at ASTCT CIBMTR Tandem Meetings! Great collaborative session on new ideas and updates on INWC papers and proposals. Welcome Medical College of Wisconsin Dr. Anna Huppler as new INWC Sci Dir! #Tandem2025

CIBMTR is now accepting applications for the CIBMTR Page Scholar Program for motivated Early Career Investigators (3-7 years from fellowship). Learn more about this unique program and apply today: cibmtr.org/CIBMTR/Utility…

JOB POSTING: CIBMTR is seeking a part time (0.1 FTE) Scientific Director to co-lead our Immunobiology Working Committee. Learn more about this important position, here: cibmtr.org/Files/Careers1…

Attending #EBMT25 beginning this weekend? Make sure to check out CIBMTR's abstracts. You can view the full list, here: cibmtr.org/Files/Meetings…

SOC Ide-cel for RRMM: A CIBMTR Analysis. N=821, median prior LOT: 7, 15% with prior anti-BCMA Rx. ORR/CR: 73/25%, median PFS: 8.8 months. NRM: 6%, SPM: 4%. #mmsm #bmtsm Surbhi Sidana, MD Nausheen Ahmed MD sganguly CIBMTR ashpublications.org/blood/article/…

One-size does not fit all: If you ever happen to see a LBCL with excellent chemosensitivity: Auto in those circumstance still reasonable. Fateeha Furqan extends our previous work now to MYC rearranged LBCL @cibmtr #bmtsm onlinelibrary.wiley.com/doi/10.1002/aj…

It was a pleasure to interview Steven Devine of NMDP recently to hear the findings of a CIBMTR retrospective analysis investigating outcomes by donor type in patients undergoing transplantation with PTCy as GvHD prophylaxis: 👉 ow.ly/7iLq50VxyHB #EBMT25 #BMTsm

Results of a new BMT CTN study show that patients who got cyclophosphamide lived longer without CGVHD, compared to patients who got other medicines. Read more: cibmtr.org/Files/Patient-…

NOW AVAILABLE: 2024 CIBMTR Summary Slides. These slides provide an annual report on data submitted by US centers to CIBMTR, detailing practices and general survival outcomes following cellular therapies. Learn more: cibmtr.org/CIBMTR/Resourc…

CIBMTR's May Newsletter is now available! Read a message from our Advisory Committee Chair, a tribute to a leader in our field, about how to access our latest Summary Slides, about two of our working committees, and more. Read online: cibmtr.org/CIBMTR/About/N…

CIBMTR is excited to announce we reached a major milestone on the CIBMTR PRO Protocol! More than 5,000 patient-reported outcomes (#PRO) surveys have now been collected from 1,700+ patients across 43 centers. Read more: cibmtr.org/CIBMTR/About/N…

The NMDP Amy Strelzer Manasevit Research Program is more than funding - it's a long-term investment in the people driving innovation in post-transplant care. If you're at the start of your research career, I encourage you to apply. ASTCT CIBMTR network.nmdp.org/research/grant…

A small BMT CTN study showed that #BMT is one good option for treating sickle cell disease in teens and young adults. Learn more about this study: cibmtr.org/Files/Patient-…

In the past, people with sickle cell disease could only get #BMT if they had a fully matched donor, but with newer medicines, people can get BMT from a half-matched donor, like a parent or sibling. Read more about this BMT CTN study: cibmtr.org/Files/Patient-…

NEW study results just published in Journal of Clinical Oncology: Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis Following Mismatched Unrelated Donor PBSC Transplantation. Read more: ascopubs.org/doi/10.1200/JC…

🚨 Thrilled to share our Journal of Clinical Oncology publication from the ACCESS study! Honored to co-chair this pivotal work at City of Hope with CIBMTR & NMDP—advancing access to life-saving #BMT 🔗 ascopubs.org/doi/10.1200/JC… 🔗 go.nmdp.org/3SRTmgf

New CIBMTR Scientific Director: Najla El Jurdi, MD, to serve as Scientific Director of Graft-versus-Host Disease Working Committee. Read more about this exciting announcement: cibmtr.org/CIBMTR/About/N…

After a partially matched transplant, #GVHD can result. Previously, partially matched donors caused more GVHD than fully matched donors in cancer patients. A new approach, using cyclophosphamide, can prevent most GVHD. Read more: cibmtr.org/Files/Patient-…

Just Published in Transplantation and Cellular Therapy Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Read more: sciencedirect.com/science/articl…

We welcome our newest Page Scholars and congratulate our inaugural group of scholars! Read more about these two wonderful groups: cibmtr.org/CIBMTR/About/N…